ZekriY, GuyotR, FlamantF.An atlas of thyroid hormone receptors' target genes in mouse tissues. Int J Mol Sci, 2022; 23(19); doi: 10.3390/ijms231911444
2.
ChatonnetF, FlamantF, MorteB. A temporary compendium of thyroid hormone target genes in brain. Biochim Biophys Acta Gene Regul Mech, 2015; 1849(2):122–129; doi: 10.1016/j.bbagrm.2014.05.023
3.
MinakhinaS, De OliveiraV, KimSY, et al.Thyroid hormone receptor phosphorylation regulates acute fasting-induced suppression of the hypothalamic-pituitary-thyroid axis. Proc Natl Acad Sci U S A, 2021; 118(39); doi: 10.1073/pnas.2107943118
4.
BiancoAC, DumitrescuA, GerebenB, et al.Paradigms of dynamic control of thyroid hormone signaling. Endocr Rev, 2019; 40(4):1000–1047; doi: 10.1210/er.2018-00275
5.
Romartinez-AlonsoB, AgostiniM, JonesH, et al.Structure-guided approach to relieving transcriptional repression in resistance to thyroid hormone α. Mol Cell Biol, 2022; 42(2):e0036321; doi: 10.1128/mcb.00363-21
6.
BochukovaE, SchoenmakersN, AgostiniM, et al.A mutation in the thyroid hormone receptor alpha gene. N Engl J Med, 2012; 366(3):243–249; doi: 10.1056/NEJMoa1110296
7.
MoranC, ChatterjeeK. Resistance to thyroid hormone α–emerging definition of a disorder of thyroid hormone action. J Clin Endocrinol Metab, 2016; 101(7):2636–2639; doi: 10.1210/jc.2016-2317
8.
FonsecaTL, RussoSC, LuongoC, et al.Inactivation of type 3 deiodinase results in life-long changes in the brown adipose tissue transcriptome in the male mouse. Endocrinology, 2022; 163(5); doi: 10.1210/endocr/bqac026
9.
MartinezME, PinzI, PredaM, et al.DIO3 protects against thyrotoxicosis-derived cranio-encephalic and cardiac congenital abnormalities. JCI Insight, 2022; 7(21); doi: 10.1172/jci.insight.161214
10.
HernandezA, MartinezME, FieringS, et al.Type 3 deiodinase is critical for the maturation and function of the thyroid axis. J Clin Invest, 2006; 116(2):476–484; doi: 10.1172/JCI26240
11.
LiaoXH, AvalosP, ShelestO, et al.AAV9-MCT8 delivery at juvenile stage ameliorates neurological and behavioral deficits in a mouse model of MCT8-deficiency. Thyroid, 2022; 32(7):849–859; doi: 10.1089/thy.2022.0034
12.
SundaramSM, Arrulo PereiraA, Müller-FielitzH, et al.Gene therapy targeting the blood-brain barrier improves neurological symptoms in a model of genetic MCT8 deficiency. Brain, 2022; doi: 10.1093/brain/awac243
13.
FriesemaEC, GruetersA, BiebermannH, et al.Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation. Lancet, 2004; 364(9443):1435–1437; doi: 10.1016/S0140-6736(04)17226-7
14.
DumitrescuAM, LiaoXH, BestTB, et al. A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene. Am J Hum Genet 2004;74(1):168–175.
15.
FaustB, BillesbølleCB, SuomivuoriC-M, et al.Autoantibody mimicry of hormone action at the thyrotropin receptor. Nature, 2022; doi: 10.1038/s41586-022-05159-1
16.
DuanJ, XuP, LuanX, et al.Hormone- and antibody-mediated activation of the thyrotropin receptor. Nature, 2022; doi: 10.1038/s41586-022-05173-3
17.
TaylorPN, AlbrechtD, ScholzA, et al.Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol, 2018; 14(5):301–316; doi: 10.1038/nrendo.2018.18
18.
KriegerCC, KahalyGJ, AzamA, et al.Graves' autoantibodies exhibit different stimulating activities in cultures of thyrocytes and orbital fibroblasts not reflected by clinical assays. Thyroid, 2022; 32(1):90–96; doi: 10.1089/thy.2021.0326
19.
FaustinoLC, KahalyGJ, FrommerL, et al.Precision medicine in Graves' disease: CD40 gene variants predict clinical response to an anti-CD40 monoclonal antibody. Front Endocrinol (Lausanne), 2021; 12(691781); doi: 10.3389/fendo.2021.691781
20.
KahalyGJ, StanMN, FrommerL, et al.A novel anti-CD40 monoclonal antibody, iscalimab, for control of graves hyperthyroidism-a proof-of-concept trial. J Clin Endocrinol Metab, 2020; 105(3); doi: 10.1210/clinem/dgz013
21.
IppolitoS, Di DalmaziG, PaniF, et al.Distinct cytokine signatures in thyroiditis induced by PD-1 or CTLA-4 blockade: Insights from a new mouse model. Thyroid, 2021; 31(12):1839–1849; doi: 10.1089/thy.2021.0165
22.
ChalanP, Di DalmaziG, PaniF, et al.Thyroid dysfunctions secondary to cancer immunotherapy. J Endocrinol Invest, 2018; 41(6):625–638; doi: 10.1007/s40618-017-0778-8
23.
LeeM, UntchBR, XuB, et al.Genomic and transcriptomic correlates of thyroid carcinoma evolution after BRAF inhibitor therapy. Mol Cancer Res, 2022; 20(1):45–55; doi: 10.1158/1541-7786.MCR-21-0442
24.
NaoumGE, MorkosM, KimB, et al.Novel targeted therapies and immunotherapy for advanced thyroid cancers. Mol Cancer, 2018; 17(1):51; doi: 10.1186/s12943-018-0786-0
25.
CrispoF, NotarangeloT, PietrafesaM, et al.BRAF inhibitors in thyroid cancer: Clinical impact, mechanisms of resistance and future perspectives. Cancers (Basel), 2019; 11(9); doi: 10.3390/cancers11091388
26.
ZhangP, GuanH, YuanS, et al.Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors. Nat Commun, 2022; 13(1):1588; doi: 10.1038/s41467-022-29000-5
